Shares of AbbVie Inc. ABBV inched 0.35% higher to $193.62 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 ...

Archon Perry Siatis is a FOUNDER of the Ecumenical Patriarch Bartholomew Foundation. In addition to serving as Vice Chair of the Archon Youth Participation Activities Committee, he is also a founding ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers, and even performed worse than an older range of treatments called triptans, said ...

The next frame shows the Ubrelvy logo in the backstage hallway along with a blue lit path. Frames six to seven then show Serena Williams walking down the blue lit path, no longer exhibiting migraine ...

A significant proportion of patients developed exocrine pancreatic insufficiency 12 months after a diagnosis of acute ...

The latest trading session saw AbbVie (ABBV) ending at $193.45, denoting a -1.16% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.03%. At the same time, the Dow ...

The stock's fall snapped a two-day winning streak.

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...

On CNBC's “Halftime Report Final Trades,” Stephen L. Weiss of Short Hills Capital Partners recommended buying TransDigm Group ...